The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical study.
about
Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defectsGuided tissue regeneration for periodontal infra-bony defectsMinimally Invasive Surgery Combined with Regenerative Biomaterials in Treating Intra-Bony Defects: A Meta-AnalysisPorcine fetal enamel matrix derivative enhances bone formation induced by demineralized freeze dried bone allograft in vivoEffect of an enamel matrix protein derivative (Emdogain) on ex vivo dental plaque vitality.Analysis of eosinophilic round bodies formed after injection of enamel matrix derivative into the backs of rats.Treatment of plaque-induced gingivitis, chronic periodontitis, and other clinical conditions.Recent approaches to periodontal therapy.Treatment of intrabony periodontal defects with enamel matrix derivative: a literature review.Periodontal regeneration - intrabony defects: a systematic review from the AAP Regeneration Workshop.Comparison of porous and non-porous teflon membranes plus a xenograft in the treatment of vertical osseous defects: a clinical reentry study.Growth and amelogenin-like factors in periodontal wound healing. A systematic review.The use of enamel matrix derivative in the treatment of periodontal defects: a literature review and meta-analysis.Which reconstructive procedures are effective for treating the periodontal intraosseous defect?Guided tissue regeneration for periodontal intrabony defects--a Cochrane Systematic Review.The relationship between baseline value and its change: problems in categorization and the proposal of a new method.Periodontal regeneration.Polymeric membranes for guided bone regeneration.Periodontal regeneration with enamel matrix derivative in reconstructive periodontal therapy: a systematic review.Enamel matrix protein derivatives: role in periodontal regeneration.Effects of enamel matrix derivative and transforming growth factor-β1 on human osteoblastic cellsInfluence of Enamel Matrix Derivative on Human Epithelial Cells In Vitro.Twenty years of enamel matrix derivative: the past, the present and the future.Porcine enamel matrix derivative enhances trabecular bone regeneration during wound healing of injured rat femur.Radiographic defect depth and width for prognosis and description of periodontal healing of infrabony defects.Comparison of clinical, radiographic, and histometric measurements following treatment with guided tissue regeneration or enamel matrix proteins in human periodontal defects.The induction of reparative dentine by enamel proteins.Stability of clinical and radiographic results after guided tissue regeneration in infrabony defects.Human periodontal fibroblast response to enamel matrix derivative, amelogenin, and platelet-derived growth factor-BB.Evaluating the quality of active-control trials in periodontal research.Enamel matrix proteins in the regenerative therapy of deep intrabony defects.The effect of enamel matrix protein derivative on follicle cells in vitro.Full length amelogenin binds to cell surface LAMP-1 on tooth root/periodontium associated cellsA primer on network meta-analysis for dental research.A comparative study utilizing open flap debridement with and without enamel matrix derivative in the treatment of periodontal intrabony defects: a 12-month re-entry study.Five-year clinical results for treatment of intrabony defects with EMD, guided tissue regeneration and open-flap debridement: a case series.Treatment of wide, shallow, and predominantly 1-wall intrabony defects with a bioabsorbable membrane: a randomized controlled clinical trial.17beta-estradiol promotes cementoblast proliferation and cementum formation in experimental periodontitis.The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins.Enamel matrix proteins and guided tissue regeneration with titanium-reinforced expanded polytetrafluoroethylene membranes in the treatment of infrabony defects: a comparative controlled clinical trial.
P2860
Q24240239-F14B72A0-3BD8-4357-B16E-ACAE6C820139Q24246192-714BA1B1-74B5-4C8F-8AD9-B87D9E43DCD2Q26770930-03CEE38F-FE34-4101-A33C-D78A5A287713Q28145305-BA682CDB-FE9F-4441-8B4D-CD550620D66DQ31027713-93315644-8F42-4D14-BC70-0AC4734BBBE2Q33226747-A93AE8DC-9520-4834-A1A8-3DBBC0080236Q34111244-A7C448AE-4D75-455A-92C1-42326FB6C04BQ34181942-AA24B66D-1CCA-4935-974E-5FAD289C464CQ35024507-CD2BB3B2-59AC-4D5A-965E-19F9F56DE658Q35250376-20A92353-7694-47B2-A830-884ECE701D93Q35545601-B5450C68-B704-4940-B857-76159F2F35DCQ35670360-FFC225AA-B7EC-4A2D-AC48-BCD4E7E800D5Q35969359-8997BDD9-37EB-41C9-BD8F-B0473ABA8013Q36011890-B3B08FEE-A5B6-4018-B0FA-2EDCC05A0E31Q36011896-5D8125A9-54E4-4872-A841-5EBC90151B7EQ36209677-8B305EED-6EC7-4562-A145-42E04011D52DQ36261011-9331A8AC-3D5E-46D1-8316-B8FD1F57EBB8Q37935688-98EE2CF4-15DD-4096-A30D-14DD28B6C404Q37952322-0E8D8663-9D84-4489-BA7F-0714E88D8D50Q38106956-85EB4171-986E-484F-81D3-1ADB145660D5Q38264457-B1156CCE-567E-4007-A99F-C671114D7325Q38763824-FE23FB40-F769-40D2-8D03-FAAFC597C6A2Q38778569-C2C6E59C-0476-46B6-A8FC-5D9795538512Q39124954-B4544137-2E26-45B8-A5F6-BC1B29C7D49CQ39591699-39C03F9D-952E-4C36-A8C6-D26A98E80359Q39601360-54E62301-0FC9-4402-B659-CDE60630F597Q39605235-9C0DA1E5-815C-4949-9080-303E6B302120Q39780196-903DB483-45BE-4AD4-BD89-2F47AD5AF9B1Q40262270-50FF5D14-F803-4651-A0D0-FB1C74E22E29Q40355170-1DF63B41-987A-4D83-BC9C-BC7C24B4F044Q40645337-BC245AE8-3641-4880-8CE8-DD83560B8653Q40800922-2F2804A4-947D-46D5-B2C9-E2431FE93EFCQ41104557-AE8436AE-3368-4E1B-970A-CA5D242E612CQ41897242-5C70AC2C-3CC3-4588-8F3A-2D7441310ECEQ42643404-3B172C10-988A-41FC-AD05-89E79795C5C9Q42659738-EB68F801-7E4C-4EE3-AE83-D9F2763D4607Q42665001-07ACA06A-49AC-4790-82F8-E8D5EF0DC367Q43137247-23AD9E29-AC60-4502-B51A-67BE92C59AB7Q43565928-1FFB8E5C-FC98-4C47-8DA1-1AFBEFE7F265Q43887084-CA388491-2453-48AD-A71A-709483332ECE
P2860
The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical study.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
The use of barrier membranes a ...... ive controlled clinical study.
@en
The use of barrier membranes a ...... ive controlled clinical study.
@nl
type
label
The use of barrier membranes a ...... ive controlled clinical study.
@en
The use of barrier membranes a ...... ive controlled clinical study.
@nl
prefLabel
The use of barrier membranes a ...... ive controlled clinical study.
@en
The use of barrier membranes a ...... ive controlled clinical study.
@nl
P2093
P1476
The use of barrier membranes a ...... ive controlled clinical study.
@en
P2093
J Wennström
R Pontoriero
P304
P356
10.1034/J.1600-051X.1997.00833.X
P407
P577
1999-12-01T00:00:00Z